Our mission is to be the leading provider of equity research in healthcare and life sciences

We produce institutional­ quality equity research on small/mid­cap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.



Research Clients



Reports published



Readers in database

Following the successful rights issue, formation of a Scientific Advisory Board and the first sales of NBT systems in Sweden, read our note on @NexstimOyj at https://t.co/DKgtKvYekJ

The ImmunoBody being developed in a collaboration between @scancellpharma and @CR_UK will use a new nanoparticle formulation in the planned Phase I/II trial in #NSCLC.
Read our note at https://t.co/mZuSJRY5Vy

Fantastic data from @MorphoSys's L-MIND study with tafasitamab (MOR208) in r/r #DLBCL - ORR of 60%, CR of 43%, mPFS of 12.1months. Looks like rituximab and the biosimilars have serious competition in B-cell lymphomas https://t.co/xecDAOhZ7m

Updated results from two Phase II trials of @BGenBio's selective #AXL inhibitor #Bemcentinib to be presented at #ASCO19.

(1) #NSCLC (bemcentinib + #pembrolizumab): https://t.co/KdjFc0L95z

(2) #AML (bemcentinib + LDAC or decitabine): https://t.co/SCbdWskrI4

.@HChiMed/@AstraZeneca's Phase II #SAVANNAH combo study of #savolitinib + #osimertinib (#Tagrisso) in c-Met+ 2L/3L EGFR/T790M #NSCLC will be profiled at #ASCO19. Trial read out is expected in 2021 & could support accelerated US approval.

.@PhrmMar’s #lurbidectedin selected for ‘Best of ASCO’. Phase II data from the 2L #SCLC lurbidectedin monotherapy trial will also be presented orally at #ASCO19 on June 1st (abstract 8906)

Subscribe to our research

Please sign up here to be added to our distribution database